A recent study published in JAMA Internal Medicine indicates that mail-order dispensing of mifepristone for medication abortion is effective, feasible, and well-received by patients. Conducted across 11 clinics in seven states, the study assessed 510 abortions among 506 participants who received mifepristone and misoprostol through the mail after an in-person eligibility screening. The results showed that 97.8% of these abortions were complete, and serious adverse events were rare, affecting only 0.6% of cases (Drugs.com) (HealthDay).
The research highlighted that 85.5% of participants received their medications within three days, and over 90% expressed willingness to use mail-order services again. The findings support the FDA’s decision to allow mail-order dispensing of abortion pills, a policy initiated during the COVID-19 pandemic to improve access and ensure safety (Drugs.com) (HealthDay).
For more details, you can read the full articles on Drugs.com and HealthDay.
